Brief: Design Therapeutics Announces FDA Clearance Of Investigational New Drug Application For First Genetac Molecule For Friedreich Ataxia
28/02/2022 21:12
Feb 28 (Reuters) - Design Therapeutics Inc DSGN.O :
* DESIGN THERAPEUTICS ANNOUNCES FDA CLEARANCE OF
INVESTIGATIONAL
NEW DRUG APPLICATION FOR FIRST GENETAC™ MOLECULE FOR FRIEDREICH
ATAXIA
* DESIGN THERAPEUTICS INC - TOPLINE DATA FROM PHASE 1 TRIAL
OF
DT-216 EXPECTED IN SECOND HALF OF 2022
* DESIGN THERAPEUTICS INC - STUDY ENROLLMENT FOR PHASE 1
CLINICAL
TRIAL OF DT-216 EXPECTED TO BEGIN IN COMING WEEKS
Source text for Eikon: ID:nGNXcffYG1
Further company coverage: DSGN.O
Recent news on Design Therapeutics
See all newsDesign Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Design Therapeutics Q2 net loss narrower than expected
Brief: Design Therapeutics Q2 Basic EPS USD -0.32
Design Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Design Therapeutics Announces Initiation Of Patient Dosing In Phase 1 Multiple Ascending Dose Trial Of Dt-818 For Myotonic Dystrophy Type-1